Discover all the actions carried out by Jeito and all the partnerships that we set up day after day for the well-being of patients and medical progress.
In the headlines
Jeito Capital portfolio company SparingVision announces strategic collaboration with Intellia Therapeutics
Partnership will allow SparingVision to develop novel genomic medicines for the treatment of ocular diseases utilizing Intellia’s proprietary CRISPR/Cas9 technology Jeito Capital selected SparingVision as its first French investment in October 2020, participating in a...
Find all our press releases
Jeito Capital leads €20 Million Investment in InnoSkel, a New Gene Therapy Company and leader in rare skeletal disorders
Jeito’s third international investment in H2 2020, with deep and rapidly accelerating pipeline...
Paris, France, 13 November 2020 – Jeito Capital (“Jeito”), a rapidly emerging independent investor...
Jeito Capital has selected SparingVision as its first French investment following the fund I...
Paris, France, 30 September 2020 – Jeito Capital (“Jeito”), a rapidly emerging independent...
Neogene becomes Jeito Capital’s first investment following the fund I launch in January 2020 Round...
Rafaèle Tordjman launches JEITO CAPITAL, a new private equity company dedicated to biotech-biopharmaceuticals
Paris, January 13, 2020 - Rafaèle Tordjman launches JEITO CAPITAL, a new French and independent...
Face to face
All day long
For more than 25 years, BIO-Europe is one of the most influential life sciences trade shows thanks to the synergies it creates in order to bring out medical innovations.
During this event, Sabine Dandigiuan, Managing Partner of Jeito Capital, will participate in the “Talent: finding it, developing it, keeping it” panel.
All day long
HealthTech Innovation Days 2021
Jeito Capital will be Silver Sponsor at HealthTech Innovation Days 2021.
Attend to Rafaèle Tordjman, MD PhD, Keynote on October, 5 at 6.30 PM CET